PittsburghV1, Main, Exploration, bibRecord, 000B55

Tissue Inhibitor Metalloproteinase-2 (TIMP-2)⋅IGF-Binding Protein-7 (IGFBP7) Levels Are Associated with Adverse Long-Term Outcomes in Patients with AKI

Identifieur interne : 000B55 ( Main/Exploration ); précédent : 000B54; suivant : 000B56

Tissue Inhibitor Metalloproteinase-2 (TIMP-2)⋅IGF-Binding Protein-7 (IGFBP7) Levels Are Associated with Adverse Long-Term Outcomes in Patients with AKI

Auteurs : Jay L. Koyner [États-Unis] ; Andrew D. Shaw [États-Unis] ; Lakhmir S. Chawla [États-Unis] ; Eric A. J. Hoste [Belgique] ; Azra Bihorac [États-Unis] ; Kianoush Kashani [États-Unis] ; Michael Haase [Allemagne] ; Jing Shi [États-Unis] ; John A. Kellum [États-Unis]

Source :

Journal of the American Society of Nephrology : JASN [ 1046-6673 ] ; 2014.

RBID : PMC:4483589

Descripteurs français

English descriptors

KwdEn :
- Acute Kidney Injury (mortality), Acute Kidney Injury (therapy), Acute Kidney Injury (urine), Adult, Biomarkers (urine), Cohort Studies, Female, Follow-Up Studies, Humans, Insulin-Like Growth Factor Binding Proteins (urine), Kaplan-Meier Estimate, Kidney Function Tests, Male, Middle Aged, Multivariate Analysis, Predictive Value of Tests, Proportional Hazards Models, Prospective Studies, Renal Dialysis (methods), Renal Dialysis (mortality), Risk Assessment, Sensitivity and Specificity, Severity of Illness Index, Survival Analysis, Time Factors, Tissue Inhibitor of Metalloproteinase-2 (urine), Treatment Outcome.
MESH :
- chemical , urine : Biomarkers, Insulin-Like Growth Factor Binding Proteins, Tissue Inhibitor of Metalloproteinase-2.
- methods : Renal Dialysis.
- mortality : Acute Kidney Injury, Renal Dialysis.
- therapy : Acute Kidney Injury.
- urine : Acute Kidney Injury.
- Adult, Cohort Studies, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Kidney Function Tests, Male, Middle Aged, Multivariate Analysis, Predictive Value of Tests, Proportional Hazards Models, Prospective Studies, Risk Assessment, Sensitivity and Specificity, Severity of Illness Index, Survival Analysis, Time Factors, Treatment Outcome.

Abstract

Tissue inhibitor metalloproteinase-2 (TIMP-2) and IGF-binding protein-7 (IGFBP7) have been validated for risk stratification in AKI. However, the association of urinary TIMP-2 and IGFBP7 with long-term outcomes is unknown. We evaluated the 9-month incidence of a composite end point of all-cause mortality or the need for RRT in a secondary analysis of a prospective observational international study of critically ill adults. Two predefined [TIMP-2]⋅[IGFBP7] cutoffs (0.3 for high sensitivity and 2.0 for high specificity) for the development of AKI were evaluated. Cox proportional hazards models were used to determine risk for the composite end point. Baseline [TIMP-2]⋅[IGFBP7] values were available for 692 subjects, of whom 382 (55.2%) subjects developed stage 1 AKI (defined by Kidney Disease Improving Global Outcomes guidelines) within 72 hours of enrollment and 217 (31.4%) subjects met the composite end point. Univariate analysis showed that [TIMP-2]⋅[IGFBP7]>2.0 was associated with increased risk of the composite end point (hazard ratio [HR], 2.11; 95% confidence interval [95% CI], 1.37 to 3.23; P<0.001). In a multivariate analysis adjusted for the clinical model, [TIMP-2]⋅[IGFBP7] levels>0.3 were associated with death or RRT only in subjects who developed AKI (compared with levels≤0.3: HR, 1.44; 95% CI, 1.00 to 2.06 for levels>0.3 to ≤2.0; P=0.05 and HR, 2.16; 95% CI, 1.32 to 3.53 for levels>2.0; P=0.002). In conclusion, [TIMP-2]⋅[IGFBP7] measured early in the setting of critical illness may identify patients with AKI at increased risk for mortality or receipt of RRT over the next 9 months.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483589

DOI: 10.1681/ASN.2014060556
PubMed: 25535301
PubMed Central: 4483589

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tissue Inhibitor Metalloproteinase-2 (TIMP-2)⋅IGF-Binding Protein-7 (IGFBP7) Levels Are Associated with Adverse Long-Term Outcomes in Patients with AKI</title>
<author><name sortKey="Koyner, Jay L" sort="Koyner, Jay L" uniqKey="Koyner J" first="Jay L." last="Koyner">Jay L. Koyner</name>
<affiliation wicri:level="2"><nlm:aff id="aff1">Section of Nephrology, Department of Medicine, University of Chicago, Chicago, Illinois;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>Section of Nephrology, Department of Medicine, University of Chicago, Chicago</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Shaw, Andrew D" sort="Shaw, Andrew D" uniqKey="Shaw A" first="Andrew D." last="Shaw">Andrew D. Shaw</name>
<affiliation wicri:level="2"><nlm:aff id="aff2">Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Tennessee</region>
</placeName>
<wicri:cityArea>Department of Anesthesiology, Vanderbilt University Medical Center, Nashville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Chawla, Lakhmir S" sort="Chawla, Lakhmir S" uniqKey="Chawla L" first="Lakhmir S." last="Chawla">Lakhmir S. Chawla</name>
<affiliation wicri:level="3"><nlm:aff id="aff3">Department of Medicine, Divisions of Intensive Care Medicine and Nephrology, Washington DC Veterans Affairs Medical Center, Washington DC;</nlm:aff>
<country>États-Unis</country>
<placeName><settlement type="city">Washington (district de Columbia)</settlement>
<region type="state">District de Columbia</region>
</placeName>
<wicri:orgArea>Department of Medicine, Divisions of Intensive Care Medicine and Nephrology, Washington DC Veterans Affairs Medical Center</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Hoste, Eric A J" sort="Hoste, Eric A J" uniqKey="Hoste E" first="Eric A. J." last="Hoste">Eric A. J. Hoste</name>
<affiliation wicri:level="1"><nlm:aff id="aff4">Department of Intensive Care Medicine, Ghent University Hospital, Ghent University, Ghent, Belgium;</nlm:aff>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Intensive Care Medicine, Ghent University Hospital, Ghent University, Ghent</wicri:regionArea>
<wicri:noRegion>Ghent</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bihorac, Azra" sort="Bihorac, Azra" uniqKey="Bihorac A" first="Azra" last="Bihorac">Azra Bihorac</name>
<affiliation wicri:level="2"><nlm:aff id="aff5">Department of Anesthesiology, University of Florida, Gainesville, Florida;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
<wicri:cityArea>Department of Anesthesiology, University of Florida, Gainesville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Kashani, Kianoush" sort="Kashani, Kianoush" uniqKey="Kashani K" first="Kianoush" last="Kashani">Kianoush Kashani</name>
<affiliation wicri:level="2"><nlm:aff id="aff6">Department of Medicine, Division of Nephrology and Hypertension and Division of Pulmonary Critical Care Medicine, Mayo Clinic, Rochester, Minnesota;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Minnesota</region>
</placeName>
<wicri:cityArea>Department of Medicine, Division of Nephrology and Hypertension and Division of Pulmonary Critical Care Medicine, Mayo Clinic, Rochester</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Haase, Michael" sort="Haase, Michael" uniqKey="Haase M" first="Michael" last="Haase">Michael Haase</name>
<affiliation wicri:level="3"><nlm:aff id="aff7">Department of Nephrology, Hypertension, Diabetes and Endocrinology, Otto von Guericke University, Magdeburg, Germany;</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Nephrology, Hypertension, Diabetes and Endocrinology, Otto von Guericke University, Magdeburg</wicri:regionArea>
<placeName><region type="land" nuts="2">Saxe-Anhalt</region>
<settlement type="city">Magdebourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shi, Jing" sort="Shi, Jing" uniqKey="Shi J" first="Jing" last="Shi">Jing Shi</name>
<affiliation wicri:level="2"><nlm:aff wicri:cut="; and" id="aff8">Statistics at Walker BioSciences, Carlsbad, California</nlm:aff>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Statistics at Walker BioSciences, Carlsbad</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Kellum, John A" sort="Kellum, John A" uniqKey="Kellum J" first="John A." last="Kellum">John A. Kellum</name>
<affiliation wicri:level="2"><nlm:aff id="aff9">Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">25535301</idno>
<idno type="pmc">4483589</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483589</idno>
<idno type="RBID">PMC:4483589</idno>
<idno type="doi">10.1681/ASN.2014060556</idno>
<date when="2014">2014</date>
<idno type="wicri:Area/Pmc/Corpus">000094</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000094</idno>
<idno type="wicri:Area/Pmc/Curation">000094</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000094</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000215</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000215</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000185</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000185</idno>
<idno type="wicri:Area/PubMed/Curation">000185</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000185</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000185</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000185</idno>
<idno type="wicri:Area/Ncbi/Merge">004567</idno>
<idno type="wicri:Area/Ncbi/Curation">004567</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004567</idno>
<idno type="wicri:doubleKey">1046-6673:2014:Koyner J:tissue:inhibitor:metalloproteinase</idno>
<idno type="wicri:Area/Main/Merge">000B67</idno>
<idno type="wicri:Area/Main/Curation">000B55</idno>
<idno type="wicri:Area/Main/Exploration">000B55</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Tissue Inhibitor Metalloproteinase-2 (TIMP-2)⋅IGF-Binding Protein-7 (IGFBP7) Levels Are Associated with Adverse Long-Term Outcomes in Patients with AKI</title>
<author><name sortKey="Koyner, Jay L" sort="Koyner, Jay L" uniqKey="Koyner J" first="Jay L." last="Koyner">Jay L. Koyner</name>
<affiliation wicri:level="2"><nlm:aff id="aff1">Section of Nephrology, Department of Medicine, University of Chicago, Chicago, Illinois;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>Section of Nephrology, Department of Medicine, University of Chicago, Chicago</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Shaw, Andrew D" sort="Shaw, Andrew D" uniqKey="Shaw A" first="Andrew D." last="Shaw">Andrew D. Shaw</name>
<affiliation wicri:level="2"><nlm:aff id="aff2">Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Tennessee</region>
</placeName>
<wicri:cityArea>Department of Anesthesiology, Vanderbilt University Medical Center, Nashville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Chawla, Lakhmir S" sort="Chawla, Lakhmir S" uniqKey="Chawla L" first="Lakhmir S." last="Chawla">Lakhmir S. Chawla</name>
<affiliation wicri:level="3"><nlm:aff id="aff3">Department of Medicine, Divisions of Intensive Care Medicine and Nephrology, Washington DC Veterans Affairs Medical Center, Washington DC;</nlm:aff>
<country>États-Unis</country>
<placeName><settlement type="city">Washington (district de Columbia)</settlement>
<region type="state">District de Columbia</region>
</placeName>
<wicri:orgArea>Department of Medicine, Divisions of Intensive Care Medicine and Nephrology, Washington DC Veterans Affairs Medical Center</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Hoste, Eric A J" sort="Hoste, Eric A J" uniqKey="Hoste E" first="Eric A. J." last="Hoste">Eric A. J. Hoste</name>
<affiliation wicri:level="1"><nlm:aff id="aff4">Department of Intensive Care Medicine, Ghent University Hospital, Ghent University, Ghent, Belgium;</nlm:aff>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Intensive Care Medicine, Ghent University Hospital, Ghent University, Ghent</wicri:regionArea>
<wicri:noRegion>Ghent</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bihorac, Azra" sort="Bihorac, Azra" uniqKey="Bihorac A" first="Azra" last="Bihorac">Azra Bihorac</name>
<affiliation wicri:level="2"><nlm:aff id="aff5">Department of Anesthesiology, University of Florida, Gainesville, Florida;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
<wicri:cityArea>Department of Anesthesiology, University of Florida, Gainesville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Kashani, Kianoush" sort="Kashani, Kianoush" uniqKey="Kashani K" first="Kianoush" last="Kashani">Kianoush Kashani</name>
<affiliation wicri:level="2"><nlm:aff id="aff6">Department of Medicine, Division of Nephrology and Hypertension and Division of Pulmonary Critical Care Medicine, Mayo Clinic, Rochester, Minnesota;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Minnesota</region>
</placeName>
<wicri:cityArea>Department of Medicine, Division of Nephrology and Hypertension and Division of Pulmonary Critical Care Medicine, Mayo Clinic, Rochester</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Haase, Michael" sort="Haase, Michael" uniqKey="Haase M" first="Michael" last="Haase">Michael Haase</name>
<affiliation wicri:level="3"><nlm:aff id="aff7">Department of Nephrology, Hypertension, Diabetes and Endocrinology, Otto von Guericke University, Magdeburg, Germany;</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Nephrology, Hypertension, Diabetes and Endocrinology, Otto von Guericke University, Magdeburg</wicri:regionArea>
<placeName><region type="land" nuts="2">Saxe-Anhalt</region>
<settlement type="city">Magdebourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shi, Jing" sort="Shi, Jing" uniqKey="Shi J" first="Jing" last="Shi">Jing Shi</name>
<affiliation wicri:level="2"><nlm:aff wicri:cut="; and" id="aff8">Statistics at Walker BioSciences, Carlsbad, California</nlm:aff>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Statistics at Walker BioSciences, Carlsbad</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Kellum, John A" sort="Kellum, John A" uniqKey="Kellum J" first="John A." last="Kellum">John A. Kellum</name>
<affiliation wicri:level="2"><nlm:aff id="aff9">Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of the American Society of Nephrology : JASN</title>
<idno type="ISSN">1046-6673</idno>
<idno type="eISSN">1533-3450</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute Kidney Injury (mortality)</term>
<term>Acute Kidney Injury (therapy)</term>
<term>Acute Kidney Injury (urine)</term>
<term>Adult</term>
<term>Biomarkers (urine)</term>
<term>Cohort Studies</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Insulin-Like Growth Factor Binding Proteins (urine)</term>
<term>Kaplan-Meier Estimate</term>
<term>Kidney Function Tests</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Multivariate Analysis</term>
<term>Predictive Value of Tests</term>
<term>Proportional Hazards Models</term>
<term>Prospective Studies</term>
<term>Renal Dialysis (methods)</term>
<term>Renal Dialysis (mortality)</term>
<term>Risk Assessment</term>
<term>Sensitivity and Specificity</term>
<term>Severity of Illness Index</term>
<term>Survival Analysis</term>
<term>Time Factors</term>
<term>Tissue Inhibitor of Metalloproteinase-2 (urine)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse de survie</term>
<term>Analyse multivariée</term>
<term>Atteinte rénale aigüe ()</term>
<term>Atteinte rénale aigüe (mortalité)</term>
<term>Atteinte rénale aigüe (urine)</term>
<term>Dialyse rénale ()</term>
<term>Dialyse rénale (mortalité)</term>
<term>Estimation de Kaplan-Meier</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Humains</term>
<term>Indice de gravité médicale</term>
<term>Inhibiteur tissulaire de métalloprotéinase-2 (urine)</term>
<term>Marqueurs biologiques (urine)</term>
<term>Modèles de hasards proportionnels</term>
<term>Mâle</term>
<term>Protéines de liaison aux IGF (urine)</term>
<term>Résultat thérapeutique</term>
<term>Sensibilité et spécificité</term>
<term>Tests de la fonction rénale</term>
<term>Valeur prédictive des tests</term>
<term>Études de cohortes</term>
<term>Études de suivi</term>
<term>Études prospectives</term>
<term>Évaluation des risques</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="urine" xml:lang="en"><term>Biomarkers</term>
<term>Insulin-Like Growth Factor Binding Proteins</term>
<term>Tissue Inhibitor of Metalloproteinase-2</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Renal Dialysis</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Acute Kidney Injury</term>
<term>Renal Dialysis</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Atteinte rénale aigüe</term>
<term>Dialyse rénale</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Acute Kidney Injury</term>
</keywords>
<keywords scheme="MESH" qualifier="urine" xml:lang="en"><term>Acute Kidney Injury</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Cohort Studies</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Kaplan-Meier Estimate</term>
<term>Kidney Function Tests</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Multivariate Analysis</term>
<term>Predictive Value of Tests</term>
<term>Proportional Hazards Models</term>
<term>Prospective Studies</term>
<term>Risk Assessment</term>
<term>Sensitivity and Specificity</term>
<term>Severity of Illness Index</term>
<term>Survival Analysis</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" qualifier="urine" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse de survie</term>
<term>Analyse multivariée</term>
<term>Atteinte rénale aigüe</term>
<term>Dialyse rénale</term>
<term>Estimation de Kaplan-Meier</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Humains</term>
<term>Indice de gravité médicale</term>
<term>Inhibiteur tissulaire de métalloprotéinase-2</term>
<term>Marqueurs biologiques</term>
<term>Modèles de hasards proportionnels</term>
<term>Mâle</term>
<term>Protéines de liaison aux IGF</term>
<term>Résultat thérapeutique</term>
<term>Sensibilité et spécificité</term>
<term>Tests de la fonction rénale</term>
<term>Valeur prédictive des tests</term>
<term>Études de cohortes</term>
<term>Études de suivi</term>
<term>Études prospectives</term>
<term>Évaluation des risques</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Tissue inhibitor metalloproteinase-2 (TIMP-2) and IGF-binding protein-7 (IGFBP7) have been validated for risk stratification in AKI. However, the association of urinary TIMP-2 and IGFBP7 with long-term outcomes is unknown. We evaluated the 9-month incidence of a composite end point of all-cause mortality or the need for RRT in a secondary analysis of a prospective observational international study of critically ill adults. Two predefined [TIMP-2]<italic>⋅</italic>
[IGFBP7] cutoffs (0.3 for high sensitivity and 2.0 for high specificity) for the development of AKI were evaluated. Cox proportional hazards models were used to determine risk for the composite end point. Baseline [TIMP-2]<italic>⋅</italic>
[IGFBP7] values were available for 692 subjects, of whom 382 (55.2%) subjects developed stage 1 AKI (defined by Kidney Disease Improving Global Outcomes guidelines) within 72 hours of enrollment and 217 (31.4%) subjects met the composite end point. Univariate analysis showed that [TIMP-2]<italic>⋅</italic>
[IGFBP7]>2.0 was associated with increased risk of the composite end point (hazard ratio [HR], 2.11; 95% confidence interval [95% CI], 1.37 to 3.23; <italic>P</italic>
<0.001). In a multivariate analysis adjusted for the clinical model, [TIMP-2]<italic>⋅</italic>
[IGFBP7] levels>0.3 were associated with death or RRT only in subjects who developed AKI (compared with levels≤0.3: HR, 1.44; 95% CI, 1.00 to 2.06 for levels>0.3 to ≤2.0; <italic>P</italic>
=0.05 and HR, 2.16; 95% CI, 1.32 to 3.53 for levels>2.0; <italic>P</italic>
=0.002). In conclusion, [TIMP-2]<italic>⋅</italic>
[IGFBP7] measured early in the setting of critical illness may identify patients with AKI at increased risk for mortality or receipt of RRT over the next 9 months.</p>
</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Belgique</li>
<li>États-Unis</li>
</country>
<region><li>Californie</li>
<li>District de Columbia</li>
<li>Floride</li>
<li>Illinois</li>
<li>Minnesota</li>
<li>Pennsylvanie</li>
<li>Saxe-Anhalt</li>
<li>Tennessee</li>
</region>
<settlement><li>Magdebourg</li>
<li>Washington (district de Columbia)</li>
</settlement>
</list>
<tree><country name="États-Unis"><region name="Illinois"><name sortKey="Koyner, Jay L" sort="Koyner, Jay L" uniqKey="Koyner J" first="Jay L." last="Koyner">Jay L. Koyner</name>
</region>
<name sortKey="Bihorac, Azra" sort="Bihorac, Azra" uniqKey="Bihorac A" first="Azra" last="Bihorac">Azra Bihorac</name>
<name sortKey="Chawla, Lakhmir S" sort="Chawla, Lakhmir S" uniqKey="Chawla L" first="Lakhmir S." last="Chawla">Lakhmir S. Chawla</name>
<name sortKey="Kashani, Kianoush" sort="Kashani, Kianoush" uniqKey="Kashani K" first="Kianoush" last="Kashani">Kianoush Kashani</name>
<name sortKey="Kellum, John A" sort="Kellum, John A" uniqKey="Kellum J" first="John A." last="Kellum">John A. Kellum</name>
<name sortKey="Shaw, Andrew D" sort="Shaw, Andrew D" uniqKey="Shaw A" first="Andrew D." last="Shaw">Andrew D. Shaw</name>
<name sortKey="Shi, Jing" sort="Shi, Jing" uniqKey="Shi J" first="Jing" last="Shi">Jing Shi</name>
</country>
<country name="Belgique"><noRegion><name sortKey="Hoste, Eric A J" sort="Hoste, Eric A J" uniqKey="Hoste E" first="Eric A. J." last="Hoste">Eric A. J. Hoste</name>
</noRegion>
</country>
<country name="Allemagne"><region name="Saxe-Anhalt"><name sortKey="Haase, Michael" sort="Haase, Michael" uniqKey="Haase M" first="Michael" last="Haase">Michael Haase</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B55 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B55 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:4483589
   |texte=   Tissue Inhibitor Metalloproteinase-2 (TIMP-2)⋅IGF-Binding Protein-7 (IGFBP7) Levels Are Associated with Adverse Long-Term Outcomes in Patients with AKI
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:25535301" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a PittsburghV1

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021

Serveur d'exploration sur Pittsburgh

Tissue Inhibitor Metalloproteinase-2 (TIMP-2)⋅IGF-Binding Protein-7 (IGFBP7) Levels Are Associated with Adverse Long-Term Outcomes in Patients with AKI

Tissue Inhibitor Metalloproteinase-2 (TIMP-2)⋅IGF-Binding Protein-7 (IGFBP7) Levels Are Associated with Adverse Long-Term Outcomes in Patients with AKI

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur Pittsburgh
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.